Home › Research › TREM2 and immune genetics
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang Y, Johnson KCC, Gatti-Mays ME, Li Z.. Journal of hematology & oncology, 2022-08-28
Topic: Brain proteins, microglia and lab models
Plain-language summary
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance.
What this study adds
Evidence grade: Low
This is a narrative review. This review is about targeting tumor-resident myeloid cells for cancer immunotherapy. It contains no information relevant to treating, curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022). Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. Journal of hematology & oncology. https://doi.org/10.1186/s13045-022-01335-y
Vancouver
Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. Journal of hematology & oncology. 2022. doi:10.1186/s13045-022-01335-y. PMID: 36031601.
BibTeX
@article{wang2022-36031601,
author = {Wang, Y. and Johnson, K. C. C. and Gatti-Mays, M. E. and Li, Z.},
title = {{Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy}},
journal = {Journal of hematology \& oncology},
year = {2022},
doi = {10.1186/s13045-022-01335-y},
pmid = {36031601},
url = {https://doi.org/10.1186/s13045-022-01335-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit.
- A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance.
- Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished.
- However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination.
Why it matters
This review is about targeting tumor-resident myeloid cells for cancer immunotherapy. It contains no information relevant to treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of hematology & oncology) |
| Journal's citation record | 2 / 4 | Journal of Hematology & Oncology: journal h-index 231 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 135 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 9.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 3 / 4 | Cited 92 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Zihai Li: h-index 69 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The Ohio State University: institution h-index 1,378 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36031601) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13045-022-01335-y
- PubMed: 36031601
- Original source →
- Free full text: Journal of Hematology & Oncology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in TREM2 and immune genetics from nearby years
Also in TREM2 and immune genetics
83 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.